Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population

Context: Lung cancer has been the most common cancer in the world for several decades. Pemetrexed is recommended as an option for the maintenance treatment in metastatic adenocarcinoma lung, if disease has not progressed immediately following platinum-based chemotherapy. Aims: To study efficacy and...

Full description

Bibliographic Details
Main Authors:	Goyal Pankaj, Batra Ullas, Dinesh Chandra Doval, Jain Parveen, Upadhyay Kumar Amitabh, Prasanta Kumar Dash, Jain Akhil, Agarwal Mohit, Bajaj Rajat
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2016-01-01
Series:	South Asian Journal of Cancer
Subjects:	Adenocacinoma lung pemetrexed pemetrexed maintenance
Online Access:	http://journal.sajc.org/article.asp?issn=2278-330X;year=2016;volume=5;issue=4;spage=196;epage=203;aulast=Pankaj

Similar Items

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
by: Lin Z, et al.
Published: (2017-11-01)

Efficacy and Toxicity of Maintenance Pemetrexed Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-small-cell Non-squamous Carcinoma of the Lung
by: Kim D. H., et al.
Published: (2015-06-01)

Pemetrexed induced pneumonitis
by: Binod Dhakal, et al.
Published: (2011-11-01)

Pemetrexed Alone versus Pemetrexed Combined with Oxaliplatin as Salvage Therapy  in Stage IV Lung Adenocarcinoma
by: Youru LIU, et al.
Published: (2011-09-01)

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer
by: Shao-Lun Lu, et al.
Published: (2016-08-01)

New Polymorphic Forms of Pemetrexed Diacid and Their Use for the Preparation of Pharmaceutically Pure Amorphous and Hemipentahydrate Forms of Pemetrexed Disodium
by: Olga Michalak, et al.
Published: (2015-07-01)

Synthesis and Physicochemical Characterization of the Impurities of Pemetrexed Disodium, an Anticancer Drug
by: Olga Michalak, et al.
Published: (2015-05-01)

Predictive factors for long‐term responders of pemetrexed maintenance treatment in non‐small cell lung cancer
by: Joon‐Young Yoon, et al.
Published: (2019-04-01)

Clinical case of long-term pemetrexed-based chemotherapy treatment for pulmonary adenocarcinoma (ALA +)
by: A. M. Lozhkina, et al.
Published: (2018-11-01)

Efficacy of Pemetrexed as Second-line Therapy or Beyond in Patients  with Advanced Non-small Cell Lung Cancer
by: Junling LI, et al.
Published: (2012-03-01)

Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with  Malignant Pleural Mesothelioma
by: Xiaomei ZENG, et al.
Published: (2022-01-01)

Clinical Investigation of Efficacy of Third-line and Beyond Pemetrexed Treatment in Advanced Non-squamous Non-small Cell Lung Cancer
by: Fei YU, et al.
Published: (2012-02-01)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
by: Zhou Ling, et al.
Published: (2023-03-01)

A Randomized Clinical Study of Gefitinib and Pemetrexed as Second Line Therapy  for Advanced Non-squamous Non-small Cell Lung Cancer
by: Hongyu DAI, et al.
Published: (2013-08-01)

Long-term exposure to pemetrexed induces chronic renal dysfunction in patients with advanced and recurrent non-squamous cell lung cancer: a retrospective study
by: Kengo Umehara, et al.
Published: (2020-10-01)

Pemetrexed in Previously Treated Non-small Cell Lung Cancer Patients with Poor Performance Status
by: Sun Young JUNG, et al.
Published: (2011-01-01)

Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum‐pemetrexed: The first report of two cases
by: Xiaoyan Si, et al.
Published: (2020-08-01)

Clinical Investigation of Efficacy of Pemetrexed in 32 Patients with Pulmonary Adenocarcinoma after Failure to Chemotherapy and Gefitinib
by: Biao WU, et al.
Published: (2010-08-01)

Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review
by: Tito Zattera, et al.
Published: (2017-04-01)

Efficacy of Bevacizumab Combined with Pemetrexed in the Treatment of Recurrent and Metastatic Cervical Cancer
by: Ying He, et al.
Published: (2022-05-01)

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
by: Yan Wang, et al.
Published: (2018-03-01)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
by: Schuette W, et al.
Published: (2017-11-01)

Pemetrexed for Ovarian Cancer: A Systematic Review of the Published Literature and a Consecutive Series of Patients Treated in a Nonclinical Trial Setting
by: Heidi Egloff, et al.
Published: (2014-07-01)

A meta-analysis of Pemetrexed plus Platinum Chemotherapy versus Gemcitabine plus Platinum Chemotherapy for Advanced Non-small Cell Lung Cancer
by: Jin JIANG, et al.
Published: (2011-01-01)

A Case of Posterior Reversible Encephalopathy Syndrome Induced by Cisplatin/Pemetrexed Chemotherapy for Lung Cancer
by: Masashi Ishihara, et al.
Published: (2017-03-01)

Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report
by: Linda Sakhri, et al.
Published: (2017-09-01)

Are 5-7 Days of Folic Acid Supplementation Necessary prior to Pemetrexed Observations from a Case Series
by: Benjamin R. Griffin, et al.
Published: (2013-06-01)

Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer
by: Chung-Yu Chen, et al.
Published: (2020-10-01)

Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS
by: Andy Liu, et al.
Published: (2023-09-01)

A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
by: Mubarak Nabil, et al.
Published: (2012-09-01)

Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study
by: Minami Seigo, et al.
Published: (2012-07-01)

Safety and efficacy of pemetrexed for the treatment of lung adenocarcinoma in patients with various stages of chronic kidney disease
by: Jieun Yang, et al.
Published: (2022-04-01)

Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321
by: Takashi Kasai, et al.
Published: (2023-07-01)

Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients
by: Bo Jia, et al.
Published: (2020-12-01)

A Novel Intergenic Region (chr2: 30,316,870)-ALK Fusion in a Patient with Lung Adenocarcinoma Responding to Crizotinib Combined with Pemetrexed Treatment: A Case Report
by: Zhou D, et al.
Published: (2024-03-01)

Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study
by: Xin Li, et al.
Published: (2021-05-01)

A Case Report on Successful Third Challenge to the Pemetrexed-based Regimen for Advanced Non-small Cell Lung Cancer
by: Linlin CHENG, et al.
Published: (2019-06-01)

Integration of metabolomics and machine learning revealed tryptophan metabolites are sensitive biomarkers of pemetrexed efficacy in non‐small cell lung cancer
by: Runbin Sun, et al.
Published: (2023-09-01)

Pneumothorax during Pemetrexed Treatment in a Patient with Non-Small Cell Lung Cancer: A Case Report and Literature Review
by: Yoshiro Nakahara, et al.
Published: (2017-05-01)

Effect of Formulation Factors and Oxygen Levels on the Stability of Aqueous Injectable Solution Containing Pemetrexed
by: Dong Han Won, et al.
Published: (2020-01-01)